Heptares Therapeutics is a drug discovery company that specializes in creating purified, stabilized, and functional GPCRs known as StaRs. This breakthrough technology overcomes a major obstacle in developing new drugs targeting GPCRs, the largest family of druggable targets. With a focus on neurology, immunology, gastroenterology, and inflammatory diseases, Heptares has an extensive pipeline of novel medicines. They have formed partnerships with renowned pharmaceutical companies like AbbVie, AstraZeneca, Genentech, and Pfizer, as well as emerging technology companies. Headquartered in Tokyo, Japan, with R&D facilities in Cambridge, UK, Heptares is the corporate brand of Sosei Group Corporation, listed on the Tokyo Stock Exchange. For more information, visit www.soseiheptares.com.